Comparison of people with hemophilia A and patients with non-valvular atrial fibrillation on oral anticoagulation by thrombin generation [0.03%]
血友病A患者与口服抗凝药物的非瓣膜性房颤患者的凝血比较研究——凝血酶生成法
Daniel Kraemmer,Cihan Ay,Judit Rejtö et al.
Daniel Kraemmer et al.
Recently published guidance on anticoagulation in people with hemophilia (PWH) appraised the literature on whether PWH are naturally anticoagulated: Only two studies compared thrombin generation (TG) in PWH and patients on vitamin K antagon...
Synergistic Thrombolysis-Antiplatelet Therapy of Engineered tPA Variant citPA5 and Tirofiban in a Mouse Stroke Model [0.03%]
组织型纤溶酶原激活剂突变体citPA5与替罗非班在小鼠脑卒中模型中的协同溶栓抗血小板治疗研究
Honglian Zhang,Guiping Xiao,Hao Li et al.
Honglian Zhang et al.
Acute ischemic stroke is a leading cause of global disability and mortality. Current therapies are limited by a narrow 4.5-hour treatment window, high risk of bleeding, frequent reocclusion post-thrombolysis, and poor neuroprotective/repair...
Conor Bell,James D Douketis
Conor Bell
Association of Longitudinal Fibrinogen Trajectories with Mortality in Sepsis: A Group-based Trajectory Analysis [0.03%]
基于群体的轨迹分析在脓毒症中纵向纤维蛋白原轨迹与死亡率的关系
Jiamei Li,Ruohan Li,Yanli Hou et al.
Jiamei Li et al.
Longitudinal fibrinogen (FIB) trajectories in sepsis and their relationship with outcomes remain poorly understood. This study aimed to identify distinct FIB trajectories and their association with outcomes.This retrospective cohort study i...
The proline-rich tyrosine kinase Pyk2 regulates platelet activation and microvascular thrombosis in a model of low grade endotoxemia [0.03%]
脯氨酰化酪氨酸蛋白激酶Pyk2调节内毒素血症小鼠模型中的血小板活化和微血管栓塞形成
Michela Gemme,Luca Galgano,Serena Rustichelli et al.
Michela Gemme et al.
The proline-rich tyrosine kinase Pyk2 is highly expressed in platelets, where it regulates platelet activation, primary hemostasis, arterial and venous thrombosis. Recently a role for Pyk2 in acute lung injury and polymicrobial sepsis has b...
Extended Rivaroxaban Therapy for Cancer-Associated Low-Risk Pulmonary Embolism by Chemotherapy Status: Insights from the ONCO PE Trial [0.03%]
基于化疗状态的癌症相关低风险肺血栓患者使用利伐沙班延长治疗的疗效和安全性：来自ONCO-PE试验的见解
Wei Xiong,Dongmei Wang,Fengfeng Han et al.
Wei Xiong et al.
The ONCO PE trial demonstrated the superiority of 18-month compared with 6-month rivaroxaban treatment for cancer-associated acute low-risk pulmonary embolism (PE) in reducing recurrent venous thromboembolism (VTE). However, it was uncertai...
Clinical Trial
Thrombosis and haemostasis. 2026 May 15. DOI:10.1055/a-2868-2803 2026
F8 genotype and immune tolerance induction outcome in people with hemophilia A and inhibitors: A systematic review and meta-analysis [0.03%]
八因子基因型与甲型血友病患者的免疫耐受诱导结局：系统评价和.meta.分析
Júlia de Oliveira Barbosa,Isabella de Oliveira Barbosa,Renan Pedra Souza et al.
Júlia de Oliveira Barbosa et al.
Background: F8 genotype is recognized as a risk factor for development of anti-factor VIII (FVIII) neutralizing alloantibodies (inhibitors) in people with hemophilia A (PwHA). However, little is known about the impact of ...
Impact of Atrial Fibrillation on Thrombotic Complications in Myeloproliferative Neoplasms Real-World Analysis [0.03%]
房颤对真性红细胞增多症及原发性血小板增多症患者血栓并发症影响的现实世界研究分析
Olga Demska,Jean-Christophe Ianotto,Marta Szandruk-Bender et al.
Olga Demska et al.
Background: Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders characterized by an increased risk of thrombotic complications due to a persistent pro-thrombotic and inf...
Revisiting Platelet-Associated Tissue Factor: Methodological Concerns in Flow Cytometry Detection [0.03%]
关于与血小板相关组织因子的再研究：流式细胞检测方法问题
Nadezhda Latysheva,Bjarne Østerud,John-Bjarne Hansen et al.
Nadezhda Latysheva et al.
Thrombin Generation as a Potential Surrogate Marker of Hemostatic Status in the Era of Novel Therapies for Hemophilia [0.03%]
新型血友病药物时代凝血酶生成作为潜在的止血状态替代标志物
Yesim Dargaud,Giancarlo Castaman,Roberta Gualtierotti et al.
Yesim Dargaud et al.
The hemophilia treatment landscape has been profoundly reshaped by non-factor therapies (NFT), which provide effective prophylaxis regardless of inhibitor status while reducing treatment burden through subcutaneous administration. However, ...